NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) issued its earnings results on Wednesday, November, 13th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.54. View Aridis Pharmaceuticals' Earnings History.

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

5 brokers have issued 1 year target prices for Aridis Pharmaceuticals' shares. Their forecasts range from $7.00 to $25.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $17.40 in the next year. This suggests a possible upside of 135.1% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

Headlines about ARDS stock have been trending positive on Thursday, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Aridis Pharmaceuticals.

Aridis Pharmaceuticals saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 41,800 shares, a decrease of 21.7% from the January 30th total of 53,400 shares. Based on an average daily trading volume, of 17,500 shares, the short-interest ratio is currently 2.4 days. Currently, 0.8% of the company's shares are short sold. View Aridis Pharmaceuticals' Current Options Chain.

Some companies that are related to Aridis Pharmaceuticals include Hookipa Pharma (HOOK), Gemphire Therapeutics (GEMP), BIOFRONTERA AG/ADR (BFRA), Ocular Therapeutix (OCUL), Kalvista Pharmaceuticals (KALV), Seres Therapeutics (MCRB), MEI Pharma (MEIP), Protagonist Therapeutics (PTGX), IVERIC bio (ISEE), Geron (GERN), XOMA (XOMA), Kala Pharmaceuticals (KALA), VBI Vaccines (VBIV), Sol Gel Technologies (SLGL) and Theratechnologies (THERF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Tandem Diabetes Care (TNDM), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Gilead Sciences (GILD) and Krystal Biotech (KRYS).

(ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDS stock can currently be purchased for approximately $7.40.

Aridis Pharmaceuticals has a market capitalization of $65.93 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]